Richard T Hinkle

Summary

Affiliation: The Procter and Gamble Company
Country: USA

Publications

  1. ncbi Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice
    Richard T Hinkle
    Research Division, Procter and Gamble Pharmaceuticals, Mason, OH, USA
    BMC Med 5:18. 2007
  2. ncbi Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy
    Richard T Hinkle
    Research Division, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, Ohio 45040, USA
    Muscle Nerve 32:775-81. 2005
  3. ncbi Modifications of the human urocortin 2 peptide that improve pharmacological properties
    Robert J Isfort
    Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason Montgomery Rd, Mason, OH 45040, USA
    Peptides 27:1806-13. 2006
  4. ncbi Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animals
    Richard T Hinkle
    Research Division, Procter and Gamble Company, Mason, OH, USA
    BMC Musculoskelet Disord 12:15. 2011
  5. ncbi Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions
    Deborah L Reichart
    Research Division, Procter and Gamble, Mason, OH, USA
    BMC Musculoskelet Disord 12:27. 2011
  6. ncbi Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions
    Richard T Hinkle
    Research Division, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason Montgomery Road, Mason, OH 45040 9317, USA
    Am J Physiol Endocrinol Metab 285:E889-98. 2003
  7. ncbi Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force
    Richard T Hinkle
    Research Division, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason Montgomery Rd, Mason, OH 45040 9317, USA
    J Appl Physiol 98:655-62. 2005
  8. ncbi Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy
    Robert J Isfort
    Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason Montgomery Road, Mason, Ohio 45040, USA
    J Med Chem 48:262-5. 2005
  9. ncbi Corticotropin-releasing factor 2 receptor localization in skeletal muscle
    Steven Samuelsson
    Research Division, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, OH 45040-9317, USA
    J Histochem Cytochem 52:967-77. 2004
  10. ncbi Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function
    Richard T Hinkle
    Research Division, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, Ohio 45040-9317, USA
    Endocrinology 144:4939-46. 2003

Collaborators

Detail Information

Publications10

  1. ncbi Corticortophin releasing factor 2 receptor agonist treatment significantly slows disease progression in mdx mice
    Richard T Hinkle
    Research Division, Procter and Gamble Pharmaceuticals, Mason, OH, USA
    BMC Med 5:18. 2007
    ..Importantly, progressive loss of diaphragm function is the most consistent striated muscle effect observed in the mdx mouse model, which is the same as in patients suffering from Duchenne muscular dystrophy...
  2. ncbi Phosphodiesterase 4 inhibition reduces skeletal muscle atrophy
    Richard T Hinkle
    Research Division, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, Ohio 45040, USA
    Muscle Nerve 32:775-81. 2005
    ..These studies indicate that PDE 4 inhibitors may have a role in the treatment of skeletal muscle-wasting diseases...
  3. ncbi Modifications of the human urocortin 2 peptide that improve pharmacological properties
    Robert J Isfort
    Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason Montgomery Rd, Mason, OH 45040, USA
    Peptides 27:1806-13. 2006
    ..In addition, attempts to shorten urocortin 2 generally resulted in inactive peptides, demonstrating that the 38 amino acid urocortin 2 peptide is the minimal pharmacophore...
  4. ncbi Treatment with a corticotrophin releasing factor 2 receptor agonist modulates skeletal muscle mass and force production in aged and chronically ill animals
    Richard T Hinkle
    Research Division, Procter and Gamble Company, Mason, OH, USA
    BMC Musculoskelet Disord 12:15. 2011
    ..Corticotrophin releasing factor 2 receptor (CRF2R) agonists have been shown to maintain skeletal muscle mass and force production in a variety of acute conditions that lead to skeletal muscle wasting...
  5. ncbi Activation of the dopamine 1 and dopamine 5 receptors increase skeletal muscle mass and force production under non-atrophying and atrophying conditions
    Deborah L Reichart
    Research Division, Procter and Gamble, Mason, OH, USA
    BMC Musculoskelet Disord 12:27. 2011
    ..Thus we hypothesize that activation of the dopamine 1 and/or 5 receptor will increase skeletal muscle cAMP levels thereby modulating skeletal muscle mass and force production...
  6. ncbi Activation of the CRF 2 receptor modulates skeletal muscle mass under physiological and pathological conditions
    Richard T Hinkle
    Research Division, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason Montgomery Road, Mason, OH 45040 9317, USA
    Am J Physiol Endocrinol Metab 285:E889-98. 2003
    ..In addition, selective activation of the CRF2R increased nonatrophy skeletal muscle mass. Thus we describe for the first time a novel activity of the CRF2R, modulation of skeletal muscle mass...
  7. ncbi Activation of the vasoactive intestinal peptide 2 receptor modulates normal and atrophying skeletal muscle mass and force
    Richard T Hinkle
    Research Division, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason Montgomery Rd, Mason, OH 45040 9317, USA
    J Appl Physiol 98:655-62. 2005
    ..These studies indicate that VPAC2R agonists may have utility for the treatment of skeletal muscle-wasting diseases...
  8. ncbi Discovery of corticotropin releasing factor 2 receptor selective sauvagine analogues for treatment of skeletal muscle atrophy
    Robert J Isfort
    Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason Montgomery Road, Mason, Ohio 45040, USA
    J Med Chem 48:262-5. 2005
    ....
  9. ncbi Corticotropin-releasing factor 2 receptor localization in skeletal muscle
    Steven Samuelsson
    Research Division, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, OH 45040-9317, USA
    J Histochem Cytochem 52:967-77. 2004
    ..The localization of the CRF2R to blood vessels is consistent with the CRF2R-mediated vascular phenomena observed previously, but the observation of CRF2R in neural tissue in skeletal muscle is a novel finding with an unknown function...
  10. ncbi Urocortin II treatment reduces skeletal muscle mass and function loss during atrophy and increases nonatrophying skeletal muscle mass and function
    Richard T Hinkle
    Research Division, Procter and Gamble Pharmaceuticals, Health Care Research Center, 8700 Mason-Montgomery Road, Mason, Ohio 45040-9317, USA
    Endocrinology 144:4939-46. 2003
    ..Therefore, CRF2R-selective agonists may find utility in the treatment of skeletal muscle wasting diseases including age-related muscle loss or sarcopenia...